DGAP-News: Dr. Hans Stocker (61) will resign as EVP Regulatory Affairs of Cytos Biotechnology Ltd at the end of 2010
(firmenpresse) - Cytos Biotechnology AG / Key word(s): Change of Personnel
28.09.2010 17:45
Publication of a media release
---------------------------------------------------------------------------
Schlieren (Zurich), Switzerland, September 28, 2010 - Cytos Biotechnology
Ltd (SIX:CYTN) informs today that Dr. Hans Stocker (61) wishes to make
use of the possibility of early retirement and plans to resign from his
operational role as EVP Regulatory Affairs of Cytos Biotechnology Ltd at
the end of the year 2010. To secure his further valuable support and long
years of experience, Dr. Hans Stocker has agreed to serve as a consultant
to the company for specific projects.
Dr. Wolfgang Renner, CEO of Cytos Biotechnology said: 'We all would like to
thank Hans Stocker for his great contributions to the company and for
building up our regulatory affairs function. We wish him a lot of joy and
fulfillment in pursuing his personal interests.'
About Cytos Biotechnology
Cytos Biotechnology Ltd is a public Swiss biotechnology company that
specializes in the discovery, development and commercialization of a new
class of biopharmaceutical products - the Immunodrugs(TM). Immunodrugs(TM)
are intended for use in the treatment and prevention of common chronic
diseases, which afflict millions of people worldwide. Immunodrugs(TM) are
designed to instruct the patient's immune system to produce desired
therapeutic antibody or T cell responses that modulate chronic disease
processes. Taking advantage of the high flexibility of its Immunodrug(TM)
platform, Cytos Biotechnology has built a diversified pipeline of
Immunodrug(TM) candidates in various disease areas, of which six are
currently in clinical development. The Immunodrug(TM) candidates are
developed both in-house and together with Novartis, Pfizer and Pfizer
Animal Health. Founded in 1995 as a spinoff from the Swiss Federal
Institute of Technology (ETH) in Zurich, the Company is located in
Schlieren (Zurich). Currently, the Company has 78 full-time employees.
Cytos Biotechnology Ltd is listed on the SIX Swiss Exchange (SIX:CYTN).
This foregoing press release may contain forward-looking statements that
include words or phrases such as 'are intended for', 'are designed to', or
other similar expressions. These forward-looking statements are subject to
a variety of significant uncertainties, including scientific, business,
economic and financial factors, and therefore actual results may differ
significantly from those presented. There can be no assurance that any
further therapeutic entities will enter clinical trials, that clinical
trial results will be predictive for future results, that therapeutic
entities will be the subject of filings for regulatory approval, that any
drug candidates will receive marketing approval from the U.S. Food and Drug
Administration or equivalent regulatory authorities, or that drugs will be
marketed successfully. Against the background of these uncertainties
readers should not rely on forward-looking statements. The company assumes
no responsibility to update forward-looking statements or adapt them to
future events or developments. This document does not constitute an offer
or invitation to subscribe or purchase any securities of Cytos
Biotechnology Ltd.
Wolfgang A. Renner, PhD
Chief Executive Officer
Cytos Biotechnology Ltd
Phone: +41 44 733 47 03
Fax: +41 44 733 47 04
e-Mail: wolfgang.renner(at)cytos.com
Website: www.cytos.com
28.09.2010 17:45 News transmitted by EquityStory AG.
The issuer is responsible for the contents of the release.
EquityStory publishes regulatory releases, media releases on the capital
market and press releases.
The EquityStory Group distributes authentic and real-time financial news
for over 1'300 listed companies.
The Swiss news archive can be found at www.equitystory.ch/news
---------------------------------------------------------------------------
Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Schweiz
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: info(at)cytos.com
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
Swiss Security Number: -
Listed: Freiverkehr in München, Berlin, Stuttgart; Open
Market in Frankfurt; Foreign Exchange(s) SIX
End of Announcement EquityStory News-Service
---------------------------------------------------------------------------
Datum: 28.09.2010 - 17:45 Uhr
Sprache: Deutsch
News-ID 32266
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 232 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Dr. Hans Stocker (61) will resign as EVP Regulatory Affairs of Cytos Biotechnology Ltd at the end of 2010"
steht unter der journalistisch-redaktionellen Verantwortung von
Cytos Biotechnology AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
